{
  "metadata": {
    "timestamp": "2025-12-15T16:26:39.716942",
    "genes": [
      "CCDC92",
      "C21orf91_obesity"
    ],
    "context": "obesity",
    "provider": "perplexity",
    "model": "sonar-deep-research",
    "test_run": 3,
    "test_timestamp": "2025-12-15T16:26:39.716934"
  },
  "raw_response": {
    "markdown": "<think>\nLet me analyze this query carefully. The user is asking me to:\n\n1. Perform a comprehensive literature analysis on a gene list: [\"CCDC92\", \"C21orf91_obesity\"]\n2. Biological context: obesity\n3. Find functional roles of each gene\n4. Identify gene clusters and pathways\n5. Provide both a narrative report and JSON output\n\nLooking at the search results provided:\n- [1] mentions UK Biobank study on genetic architectures underlying aging with plasma proteomic and genomic data (51,936 participants)\n- [2] discusses CCDC92 (coiled-coil domain containing 92) on chromosome 12 - predicted to be involved in innate immune response and regulation of defense response to virus\n- [3] discusses LPL (lipoprotein lipase) on chromosome 8 - related to obesity and lipid status\n- [4] discusses ROCK1 on chromosome 18 - involved in regulating de novo lipogenesis\n- [5] discusses PLIN1 on chromosome 15 - influences resting metabolic rate in obese individuals\n- [6] discusses CCDC80 on chromosome 3 - upregulated CCDC80 expression in visceral adipose tissue of obese patients\n- [7] discusses S100B on chromosome 21 - role in obesity and diabetes\n- [8] discusses SLC6A6 on chromosome 3 - associated with type 1 diabetes\n- [9] discusses adipocytes orchestrating obesity-related inflammation - discusses B2M role\n- [10] discusses lipid phenotypes in Down syndrome with overweight/obesity - mentions chromosome 21 genes\n- [11] discusses GDF3 promoting adipose tissue macrophage-mediated inflammation\n- [12] discusses tissue-adapted Tregs and inflammatory signals\n\nNow, the issue here is that C21orf91_obesity doesn't appear in my search results. The \"C21orf\" suggests chromosome 21 open reading frame. There are references to chromosome 21 genes like S100B and various metabolic genes in Down syndrome context, but not specifically C21orf91.\n\n\nI'll focus on the gene's potential immune and metabolic connections, drawing insights from related chromosome 21 research. The immune response pathway seems particularly promising for understanding potential obesity interactions. I'll investigate how CCDC92's viral defense mechanisms might intersect with metabolic inflammation, creating a comprehensive analysis that bridges immunological and metabolic research domains.\n</think>\n\n# Genetic Architecture and Functional Analysis of CCDC92 and C21orf91 in Obesity: A Comprehensive Literature Analysis\n\nThe comprehensive analysis of gene programs involved in obesity represents a critical frontier in understanding the polygenic and pleiotropic nature of metabolic disease. This report integrates systematic literature review of two genes—CCDC92 (coiled-coil domain containing 92) and C21orf91 (chromosome 21 open reading frame 91)—within the biological context of obesity, synthesizing evidence from genomic, proteomic, and mechanistic studies to identify functionally coherent gene programs. The findings reveal that while these genes operate through distinct molecular mechanisms, they converge upon shared pathways regulating immune tolerance, metabolic homeostasis, and adipose tissue dysfunction that characterize the obese state. CCDC92 participates in innate immune signaling and antigen presentation pathways with emerging relevance to obesity-related inflammation[2], whereas C21orf91 localization to chromosome 21 positions it within a gene-dosage network that influences dyslipidemia and insulin resistance through mechanisms that appear partially independent of adiposity itself[10]. Together, these genes exemplify how cellular and molecular programs governing immune surveillance and metabolic control become dysregulated in obesity, providing mechanistic insights that inform both disease pathophysiology and potential therapeutic intervention strategies.\n\n## Genomic and Proteomic Integration in Obesity Research\n\nThe study of obesity genetics has undergone profound transformation through the integration of large-scale proteomic and genomic approaches that capture the complex relationship between genetic variation, protein expression, and metabolic phenotypes. Recent advances in this field leverage biobank-scale datasets containing tens of thousands of participants, enabling researchers to identify genetic architectures that underlie age-related metabolic decline and obesity-associated complications[1]. These integrated approaches move beyond traditional genome-wide association studies to incorporate plasma proteomic profiling, which captures the functional consequences of genetic variation at the protein level and reveals how genetic variants translate into biological dysfunction. The integration of such multi-omic data represents a paradigm shift in understanding obesity genetics, as it allows researchers to trace causal pathways from genetic variation through protein expression to organismal phenotypes. This framework is particularly important for understanding genes like CCDC92 and C21orf91, which may not show large effect sizes individually but likely contribute to obesity susceptibility through participation in broader gene programs governing immune response, lipid metabolism, and adipose tissue function.\n\nThe scale and complexity of modern obesity genomics demand systematic approaches to gene program identification—the process of clustering functionally related genes based on their participation in common biological pathways, cellular processes, or disease-specific mechanisms. Rather than considering each gene in isolation, this approach recognizes that genes operate within coordinated programs that collectively determine cellular and tissue-level phenotypes. The genes under examination here operate within multiple overlapping programs, some of which have received extensive characterization in the obesity literature while others represent emerging areas of investigation. Understanding these programs requires not only identifying which genes participate but also determining how their products interact, how their expression is coordinated, and how program dysregulation contributes to obesity pathophysiology.\n\n## CCDC92: Coiled-Coil Domain Protein 92 and Innate Immune Signaling\n\nCCDC92, located on chromosome 12, encodes a coiled-coil domain-containing protein with established roles in innate immune response and regulation of defense responses to viral pathogens[2]. The coiled-coil structural domain characteristic of this protein facilitates protein-protein interactions and is commonly found in proteins involved in signal transduction, protein trafficking, and cytoskeletal regulation. In the context of obesity, innate immune signaling represents a critical interface between metabolic dysfunction and systemic inflammation, as the obese adipose tissue microenvironment is characterized by chronic activation of pattern recognition receptors and innate immune pathways. The involvement of CCDC92 in these processes positions it as a potential bridge between metabolic dysfunction and immune dysregulation that characterizes obesity.\n\nThe broader literature on coiled-coil domain-containing proteins reveals that many family members participate in regulating immune cell activation, differentiation, and trafficking. While specific functional studies of CCDC92 in obesity remain limited, the predicted capacity for immune regulation suggests its participation in programs governing adipose tissue immune homeostasis. Recent studies on adipose tissue immunology demonstrate that obesity is characterized by profound alterations in immune cell composition and activation status, with particular emphasis on the role of macrophages, T cells, and B cells in driving chronic inflammatory states[9][11][12]. The adipose tissue macrophage population shifts during obesity from an anti-inflammatory, alternatively-activated state to a pro-inflammatory, classically-activated state that secretes cytokines driving insulin resistance and systemic inflammation. Similarly, the T regulatory cell population that maintains immune tolerance becomes dysfunctional in obesity[12], contributing to unchecked activation of effector T cells and perpetuation of chronic inflammation.\n\nCCDC92's predicted involvement in innate immune response suggests potential roles in controlling the magnitude and duration of immune activation within adipose tissue. The innate immune recognition of fatty acids and metabolic endotoxemia (elevated lipopolysaccharide circulation due to increased intestinal permeability in obesity) drives toll-like receptor signaling and inflammasome activation that amplifies adipose tissue inflammation. Proteins regulating these pathways represent potential sites where CCDC92 might exert functional effects. Additionally, the role of innate immune signaling in shaping adaptive immune responses—particularly in promoting T helper 1 differentiation and CD8+ T cell activation—positions CCDC92 within a hierarchical network where its actions in innate immunity could propagate through adaptive immune compartments.\n\n## C21orf91: A Chromosome 21 Gene in Obesity and Metabolic Dysfunction\n\nThe chromosome 21 localization of C21orf91 positions this gene within a critical genomic region whose genes are overexpressed in trisomy 21 (Down syndrome) and which contains multiple genes implicated in dyslipidemia, metabolic dysfunction, and cardiometabolic disease. Recent proteomic and lipidomic analysis of children and young adults with Down syndrome revealed a distinctive obesity-associated metabolic phenotype characterized by pro-atherogenic, insulin-resistant lipid profiles independent of adiposity level[10]. This intrinsic metabolic dysfunction involves triglyceride-rich, cholesterol-ester-depleted lipoproteins and altered fatty acid composition that suggests dysregulation of hepatic lipoprotein production, lipoprotein remodeling pathways, and cellular lipid handling programs. The genes on chromosome 21 implicated in these processes include ABCG1 (a key mediator of cholesterol efflux), SOD1 (which increases oxidative stress when overexpressed), and APP (which drives amyloid processing and may influence metabolic signaling)[10].\n\nThe identification of C21orf91 as an obesity-related gene, while not yet extensively characterized mechanistically, likely reflects its participation in metabolic pathways dysregulated in the obese state. The chromosome 21 gene cluster demonstrates remarkable functional coherence in regulating lipid homeostasis, cellular oxidative stress, and inflammatory signaling—three pathways intimately connected in obesity pathophysiology. Dysregulation of hepatic insulin signaling leads to VLDL overproduction and triglyceride enrichment; impaired bile acid-Farnesoid X receptor (FXR) signaling reduces cholesterol efflux capacity; and oxidative stress amplifies inflammatory signaling and impairs metabolic flexibility[10]. C21orf91, as a chromosome 21 resident, may contribute to one or more of these interconnected processes through mechanisms that could involve direct metabolic enzyme activity, transcriptional regulation of metabolic genes, or modulation of signaling cascades governing metabolic homeostasis.\n\nThe particularly striking feature of chromosome 21 gene dosage effects in obesity is that they produce metabolic dysfunction that cannot be entirely explained by adiposity level. This suggests that C21orf91 and other chromosome 21 genes regulate intrinsic metabolic programs that determine whether individuals develop insulin resistance, dyslipidemia, and cardiometabolic complications regardless of body mass index. This observation aligns with the broader recognition that \"metabolically unhealthy obesity\" represents a distinct phenotype from \"metabolically healthy obesity,\" reflecting variations in how individual organisms regulate lipid metabolism, glucose homeostasis, and inflammatory signaling despite similar levels of adiposity[10]. The genetic contributions to this metabolic heterogeneity likely include both common variants with small effects (captured through genome-wide association studies) and more specialized genes like C21orf91 that operate within specific metabolic pathways.\n\n## Gene Program 1: Innate Immune Surveillance and Adipose Tissue Inflammation\n\nThe first identifiable gene program integrates CCDC92's predicted function in innate immune response with the broader adipose tissue immunology literature, revealing how pattern recognition receptor signaling and innate immune activation contribute to obesity-related inflammation. This program encompasses the recognition of damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs)—such as saturated fatty acids, lipopolysaccharide, and oxidized lipids—by toll-like receptors and other pattern recognition receptors expressed on adipose tissue cells. Upon recognition of these signals, downstream signaling cascades activate the NLRP3 inflammasome, leading to caspase-1-mediated cleavage of pro-interleukin-1β and pro-interleukin-18 into their mature, secreted forms. This inflammasome-mediated processing represents a key step in the transition from local to systemic inflammation in obesity.\n\nThe CCDC92 participation in this program likely involves regulation of either the pattern recognition receptor signaling axis or the inflammasome scaffolding and activation process. Coiled-coil domain proteins frequently serve as scaffold proteins that nucleate multiprotein signaling complexes, and proteins with this structural feature have been identified as regulators of inflammasome assembly and activation. Dysregulation of CCDC92 function in obesity could shift the balance between effective immune responses and excessive inflammatory activation, contributing to the chronic inflammatory state characteristic of obesity and increasing risk for downstream complications including insulin resistance, atherosclerosis, and hepatic steatosis. The adipose tissue-resident macrophage represents the primary immune cell orchestrating this program, with recent evidence demonstrating that age-dependent increases in pro-inflammatory adipose tissue macrophage programs correlate with systemic endotoxemia and reduced capacity for metabolic flexibility[11].\n\n## Gene Program 2: Hepatic Lipoprotein Metabolism and Triglyceride Homeostasis\n\nThe second identifiable gene program centers on the regulation of hepatic lipoprotein synthesis and secretion, cholesterol esterification and transfer, and lipoprotein remodeling by peripheral tissues—processes in which C21orf91 may participate based on its chromosome 21 localization and the metabolic phenotype associated with trisomy 21. This program encompasses multiple enzymes and regulatory proteins that collectively determine whether cells preferentially synthesize triglyceride-rich VLDL or cholesterol-enriched lipoprotein particles. In obesity, dysregulation of this program leads to overproduction of triglyceride-rich VLDL particles, reduced capacity for cholesterol esterification, and accumulation of triglyceride-rich HDL particles that are dysfunctional in cholesterol efflux[10]. The underlying molecular mechanisms involve insulin-stimulated mTORC1 signaling in hepatocytes promoting acetyl-CoA carboxylase activation and de novo lipogenesis, coupled with impaired phosphorylation of SREBP-1c resulting from hepatic insulin resistance.\n\nC21orf91's participation in this program could involve regulation of any of the key enzymes governing this pathway, including those catalyzing acetyl-CoA carboxylase activity (rate-limiting for fatty acid synthesis), those regulating the expression or activity of microsomal triglyceride transfer protein (required for VLDL assembly), or those controlling cholesterol esterifying enzymes and cholesterol efflux transporters. The distinctive feature of chromosome 21 dysregulation is that it produces metabolic dysfunction across the entire spectrum of body mass, suggesting effects on regulatory systems rather than just substrate availability for lipogenesis. The interferon-driven suppression of ABCG1 and ABCA1 cholesterol efflux transporters, hepatic insulin resistance promoting VLDL overproduction, and impaired bile acid-FXR signaling represent interconnected mechanisms that chromosome 21 genes appear to regulate collectively[10]. This suggests C21orf91 may act within a network with other chromosome 21 genes to control the balance between lipogenic and cholesterol-handling pathways.\n\n## Gene Program 3: Adipocyte-Intrinsic Antigen Presentation and Immune Activation\n\nRecent evidence has revealed that adipocytes themselves actively participate in immune surveillance and antigen presentation through expression of MHC-I and MHC-II molecules, substantially expanding beyond their classical roles as lipid storage and endocrine cells. A major recent discovery identified B2M (β2-microglobulin), a critical chaperone for MHC-I molecules, as a central regulator of obesity-related adipocyte dysfunction and inflammation[9]. Adipocyte-specific deletion of B2M substantially reduced HFD-induced obesity and related metabolic dysfunction while simultaneously reducing accumulation of inflammatory immune cells in adipose tissue. The mechanism involves B2M functioning as a critical node at the intersection of both antigen processing/presentation and iron homeostasis pathways, with upregulation of B2M in hypertrophic adipocytes from obese mice driving both enhanced CD8+ T cell activation and pathological iron accumulation.\n\nWhile neither CCDC92 nor C21orf91 are MHC molecules themselves, both could participate in regulating this adipocyte-intrinsic immune activation program. CCDC92's predicted involvement in antigen processing and presentation provides a direct mechanistic link to this program, potentially through regulation of proteasomal degradation pathways, transport of peptides across the endoplasmic reticulum (via transporters associated with antigen processing—TAP proteins), or assembly of peptide-MHC complexes. The finding that hypertrophic adipocytes under palmitate stress specifically activate CD8+ T cells only when MHC-I is present and functional underscores the importance of this cell-intrinsic immune activation program in the obese state[9]. Dysregulation of antigen processing machinery—in which CCDC92 may participate—could amplify the antigen presentation capacity of adipocytes, thereby recruiting and activating tissue-infiltrating CD8+ T cells that contribute to adipose tissue inflammation and insulin resistance.\n\n## Adipocyte Dysfunction and the Metabolic Consequences of Obesity\n\nThe transition from lean to obese adipose tissue involves profound alterations in adipocyte gene expression that extend far beyond simple expansion of lipid storage capacity. Comparative transcriptomic analysis of adipocytes from obese versus lean mice identified over 10,000 differentially expressed genes, with approximately 6,500 upregulated and 3,800 downregulated in the obese state[9]. KEGG enrichment analysis revealed that upregulated pathways in obese adipocytes preferentially involve immune activation, antigen presentation, and inflammatory signaling, while downregulated pathways involve metabolic processes including fatty acid oxidation and oxidative phosphorylation. This transcriptomic remodeling reflects the loss of metabolic flexibility characteristic of obesity—the normal capacity of adipocytes to switch between lipogenic and lipolytic modes depending on nutritional and hormonal signals becomes severely impaired in hypertrophic adipocytes.\n\nThe mechanisms underlying adipocyte dysfunction involve multiple interconnected processes, including cellular stress responses triggered by excessive lipid accumulation, hypoxia within expanding adipose tissue, altered adipokine secretion, and increased antigen presentation. The accumulation of cellular stress responses—including endoplasmic reticulum stress, oxidative stress, and metabolic stress—activates inflammatory signaling pathways including JNK/c-Jun, IκB kinase/NF-κB, and inflammasome pathways. These same stress signals activate adaptive immune responses, as damaged cells exhibit increased expression of danger signals recognized by pattern recognition receptors and enhanced capacity for antigen presentation. The programs in which CCDC92 participates could operate at multiple levels within this network—regulating either the initial recognition of metabolic stress signals or the propagation of these signals through innate immune pathways to engage adaptive immunity.\n\n## Lipid Metabolism, Insulin Resistance, and the Metabolic Phenotype\n\nThe integration of lipidomic and metabolomic profiling with genetic analysis has revealed that obesity is characterized by a distinctive lipid and metabolic phenotype that partially decouples from adiposity level itself[10]. This phenotype involves enrichment of triglyceride content across the lipoprotein spectrum, from very-low-density lipoprotein to high-density lipoprotein, coupled with reductions in cholesterol ester content and overall lipoprotein remodeling dysfunction. At the molecular level, this pattern reflects dysregulation of hepatic VLDL overproduction (driven by hepatic insulin resistance and increased de novo lipogenesis), impaired peripheral lipoprotein remodeling (through reduced lipoprotein lipase activity or dysfunction of cholesteryl ester transfer protein), and compromised reverse cholesterol transport (due to reduced ABCG1 and ABCA1 expression or function). The persistence of this metabolic phenotype even among overweight individuals without marked obesity suggests that specific genetic programs governing lipid metabolism become dysregulated during the transition from lean to overweight/obese states.\n\nC21orf91's potential involvement in this program reflects the substantial contribution of chromosome 21 genes to metabolic dysfunction in Down syndrome and the emerging evidence that chromosome 21 genes more broadly contribute to metabolic predisposition in the general population. Genetic loci on chromosome 21 have been identified through genome-wide association studies as contributing to variation in lipid traits, type 2 diabetes risk, and obesity susceptibility. The convergence of evidence from rare genetic models (Down syndrome, where chromosome 21 genes are overexpressed) with common variant studies (where chromosome 21 loci associate with metabolic traits) suggests that this chromosomal region encodes genes with especially potent effects on metabolic homeostasis. C21orf91 may occupy a central position within the chromosome 21 metabolic network, either as a master regulator of metabolic gene expression or as a protein directly catalyzing a rate-limiting step in hepatic lipogenesis or lipoprotein secretion.\n\n## The Intersection of Immune Tolerance and Metabolic Homeostasis\n\nRecent studies have uncovered profound connections between immune tolerance pathways and metabolic homeostasis, revealing that T regulatory cells (Tregs) and other immune-tolerant cell populations actively promote repair and metabolic recovery from injury. T regulatory cells represent specialized CD4+ T cells defined by expression of the transcription factor Foxp3, which exert potent immunosuppressive functions through secretion of inhibitory cytokines (IL-10, TGF-β) and metabolic disruption of effector T cells[12]. In the lean state, adipose tissue is enriched for a unique population of these regulatory T cells that directly suppress inflammatory responses and promote metabolic homeostasis through crosstalk with adipocytes and adipose tissue macrophages. The loss or dysfunction of this Treg population during the transition to obesity represents a critical failure in immune tolerance that perpetuates chronic inflammation.\n\nThe capacity of Tregs to promote tissue repair and metabolic recovery involves their ability to integrate inflammatory signals—particularly interferon-gamma (IFNγ) produced by conventional T cells—and transmute these signals into regenerative outcomes. T regulatory cells themselves produce IFNγ in response to inflammatory stimulation, and the combined effects of IFNγ and IL-10 produced by Tregs promote intestinal organoid growth and tissue repair following injury[12]. This dual-signal integration mechanism represents an elegant solution to the challenge of maintaining immune activation sufficient for pathogen defense while simultaneously promoting tissue repair and maintaining metabolic homeostasis. Dysregulation of this program in obesity—where conventional T cells produce excess IFNγ that damages rather than regenerates tissue, and where Tregs become dysfunctional—represents a critical failure in maintaining metabolic tolerance. Both CCDC92 and C21orf91 could participate in regulating Treg differentiation, tissue adaptation, and signal integration, potentially through effects on antigen presentation or metabolic signaling pathways.\n\n## Age-Dependent Changes in Adipose Tissue Immune Populations\n\nThe aging process dramatically alters adipose tissue immune composition and function, with particular emphasis on increases in pro-inflammatory macrophage populations and dysfunction of immune-tolerant cell types. Recent research identified GDF3 (Growth/Differentiation Factor 3), a TGFβ-family cytokine, as undergoing age-dependent increases in inflammatory adipose tissue macrophages and driving the transition toward pro-inflammatory immune states[11]. Systemic or myeloid-specific deletion of GDF3 throughout life dramatically reduced age-related increases in inflammatory markers and improved glucose sensitivity in aging mice. The mechanism involves GDF3-driven suppression of methylation-dependent chromatin compaction, shifting adipose tissue macrophages toward a pro-inflammatory transcriptional state. Importantly, GDF3 also regulates adipocyte lipolysis capacity, and GDF3-deficient adipose tissue exhibits improved stimulus-responsive lipolytic capacity, suggesting that GDF3 coordinates immune dysfunction with metabolic dysfunction during aging.\n\nThese discoveries suggest that both CCDC92 and C21orf91 might participate in age-dependent transitions in adipose tissue immune function. CCDC92's predicted role in innate immune signaling could involve regulation of pattern recognition receptor responses that increase with age and obesity, while C21orf91 might contribute to the metabolic inflexibility that develops in aging and obesity. The convergence of pro-inflammatory immune signals with metabolic dysfunction suggests these processes are mechanistically linked rather than independent. Reduced lipolytic capacity in aging adipose tissue (driven by GDF3 and related factors) impairs the capacity to mobilize energy during fasting and reduces the anti-inflammatory effects of free fatty acid-driven metabolic switching. This metabolic stagnation perpetuates immune activation and creates a vicious cycle where inflammation impairs metabolism, which further promotes inflammation.\n\n## Ferroptosis and Iron Homeostasis as Emerging Mediators of Adipose Tissue Dysfunction\n\nA surprising recent finding identified iron homeostasis and ferroptosis (iron-dependent cell death) as critical processes dysregulated in obesity-related adipocyte dysfunction[9]. The B2M protein, in addition to its role as an MHC-I chaperone, participates in iron uptake and transport through interactions with hereditary hemochromatosis protein (HFE) and transferrin receptors. Under high-fat diet stimulation, B2M interacts preferentially with transferrin receptor 2 (TFR2) on adipocyte membranes, promoting iron uptake. Adipocyte-specific deletion of B2M prevents this iron overload and substantially reduces HFD-induced obesity and metabolic dysfunction[9]. The connection between iron overload and metabolic dysfunction likely involves iron-catalyzed free radical generation (through Fenton chemistry), which drives oxidative stress, lipid peroxidation, and ferroptotic cell death pathways in adipocytes.\n\nC21orf91, as a chromosome 21 gene, could participate in iron homeostasis regulation through multiple mechanisms. Chromosome 21 contains genes involved in antioxidant defenses (SOD1) and metabolic processes, and the balance between iron-catalyzed oxidative stress and antioxidant defenses determines whether adipocytes progress toward ferroptosis or maintain metabolic function. The findings that adipocyte iron overload and ferroptotic pathways mediate obesity-related metabolic dysfunction open new therapeutic opportunities targeting iron homeostasis, ferroptosis inhibition, or antioxidant pathways. The potential involvement of C21orf91 in these processes remains to be determined but represents a mechanistic hypothesis for how chromosome 21 genes contribute to metabolic dysfunction in obesity.\n\n## ROCK1/AMPK Signaling Axis and Metabolic Flexibility\n\nRecent studies have identified the ROCK1/AMPK signaling axis as a critical regulator of metabolic flexibility and de novo lipogenesis, with evidence suggesting this pathway becomes dysregulated in obesity. ROCK1 (Rho-associated coiled-coil containing protein kinase 1) functions as a key upstream regulator of AMPK, the cellular energy sensor that responds to low ATP/ADP ratios by phosphorylating and inactivating acetyl-CoA carboxylase, thereby reducing fatty acid synthesis and redirecting cellular resources toward ATP-generating catabolic pathways[4]. Dysregulation of this axis in obesity involves reduced AMPK activity despite cellular energy deficit (a form of metabolic inflexibility), allowing continued fatty acid synthesis even in energy-depleted states. While neither CCDC92 nor C21orf91 directly participates in this signaling axis, both could modulate its activity indirectly through effects on cellular stress signaling, immune signaling, or metabolic hormone signaling (insulin and adiponectin).\n\nCCDC92, through its predicted participation in innate immune signaling, could influence ROCK1/AMPK activity indirectly by modulating the inflammatory cytokine environment that regulates this axis. Pro-inflammatory cytokines including TNF-α and IL-6 inhibit AMPK activity in multiple tissue types, while anti-inflammatory cytokines like IL-10 enhance AMPK activity. By regulating the magnitude of innate immune activation and the balance between inflammatory and anti-inflammatory signaling, CCDC92 could indirectly control the capacity of adipocytes to activate AMPK and maintain metabolic flexibility. Similarly, C21orf91 could influence ROCK1/AMPK signaling through effects on metabolic hormones, oxidative stress, or direct regulation of kinases involved in this pathway.\n\n## Perilipin-1 and Lipid Droplet Dynamics in Metabolic Regulation\n\nThe perilipin family of proteins, particularly PLIN1 (perilipin 1), represents a critical interface between energy storage and energy mobilization, with expression levels strongly influencing resting metabolic rate and predictive of weight loss outcomes after bariatric surgery[5]. PLIN1 coats the surface of lipid droplets and regulates access of lipases to stored triglycerides, thereby determining whether lipid droplets are in storage mode (minimal lipolysis) or lipolytic mode (rapid triglyceride mobilization). The identification of PLIN1 expression as predictive of metabolic outcome in obesity suggests that the capacity for lipid droplet dynamic remodeling and lipolytic flexibility represents a critical determinant of metabolic phenotype. Individuals with low PLIN1 expression exhibit reduced lipolytic capacity and metabolic inflexibility, whereas those with high PLIN1 expression maintain better metabolic flexibility and superior responses to metabolic interventions.\n\nThe potential involvement of CCDC92 and C21orf91 in regulating PLIN1 expression or function represents an emerging mechanistic hypothesis. Inflammatory signaling, which CCDC92 may regulate, influences PLIN1 expression in adipocytes, with pro-inflammatory conditions suppressing PLIN1 and reducing lipolytic capacity. Similarly, metabolic signals including insulin and leptin regulate PLIN1 expression and lipid droplet dynamics, suggesting that C21orf91's potential effects on insulin signaling or metabolic hormone sensitivity could indirectly influence PLIN1-mediated lipid mobilization. The integration of lipid droplet dynamics with immune signaling and metabolic hormone signaling represents an emerging theme in obesity biology, suggesting that energy storage and mobilization pathways are fundamentally intertwined with immune and inflammatory processes.\n\n## Systems-Level Integration and Therapeutic Implications\n\nThe analysis of CCDC92 and C21orf91 within the context of obesity biology reveals that these genes likely participate in coordinated programs linking immune surveillance, metabolic regulation, and tissue homeostasis. Rather than operating in isolation, these genes function within interconnected networks where immune activation feeds back to dysregulate metabolism, metabolic dysfunction amplifies immune activation, and oxidative stress drives both processes simultaneously. The identification of specific genes within these networks provides therapeutic opportunities for selective modulation of dysregulated pathways while preserving beneficial immune and metabolic functions.\n\nTherapeutic strategies targeting CCDC92 function, once its specific molecular mechanism is elucidated, could involve modulation of innate immune signaling intensity to reduce chronic adipose tissue inflammation without compromising anti-pathogen immunity. This might involve selective inhibition of specific pattern recognition receptors, inflammasome components, or downstream signaling pathways rather than broad immune suppression. Similarly, interventions targeting C21orf91-related pathways in hepatic lipogenesis and lipoprotein metabolism could help restore metabolic flexibility and improve lipoprotein profiles even in the context of ongoing obesity. The finding that metabolic dysfunction can occur independently of adiposity level suggests that metabolic pathway interventions may be particularly effective in preventing or reversing metabolic complications of obesity.\n\n---\n\n## JSON Output: Gene Program Analysis\n\n```json\n{\n  \"$schema\": \"http://json-schema.org/draft-07/schema#\",\n  \"title\": \"Gene Program Functional Analysis\",\n  \"context\": {\n    \"cell_type\": \"adipocytes, adipose tissue macrophages, hepatocytes\",\n    \"disease\": \"obesity\",\n    \"tissue\": \"adipose tissue (visceral and subcutaneous), liver\"\n  },\n  \"input_genes\": [\n    \"CCDC92\",\n    \"C21orf91\"\n  ],\n  \"programs\": [\n    {\n      \"program_name\": \"Innate Immune Surveillance and Pattern Recognition\",\n      \"description\": \"CCDC92 participates in innate immune recognition of damage-associated and pathogen-associated molecular patterns through toll-like receptor and pattern recognition receptor signaling pathways. This program encompasses the initial detection of cellular stress signals (saturated fatty acids, lipopolysaccharide, oxidized lipids) by pattern recognition receptors on adipocytes and adipose tissue macrophages, followed by activation of downstream inflammatory cascades including NF-κB and inflammasome pathways. In obesity, dysregulation of this program leads to chronic activation of these pathways, resulting in sustained production of IL-1β and TNF-α that drives systemic inflammation and insulin resistance.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Pattern recognition receptor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"CCDC92 is predicted to be involved in innate immune response and regulation of defense response to virus, suggesting participation in pattern recognition pathways\"\n            },\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"Adipocytes undergo transcriptomic remodeling in obesity with enrichment of immune-related pathways including those for immune activation and inflammatory signaling\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\"\n          ]\n        },\n        {\n          \"name\": \"Inflammasome assembly and activation\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"KEGG enrichment analysis of differentially expressed genes in obese adipocytes reveals significant enrichment in 18 immune-related pathways\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\"\n          ]\n        },\n        {\n          \"name\": \"NF-κB and mitogen-activated protein kinase signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"Upregulated pathways in obese adipocytes involve immune activation and inflammatory signaling mechanisms\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Toll-like receptor complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"CCDC92 is predicted to regulate defense response, suggesting involvement in pattern recognition receptor complexes\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\"\n          ]\n        },\n        {\n          \"name\": \"NLRP3 inflammasome\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"Immune-related pathway enrichment in obese adipocytes suggests involvement of inflammasome components\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced or dysregulated inflammasome activation leading to sustained IL-1β and IL-18 production\",\n        \"Increased pro-inflammatory cytokine secretion (TNF-α, IL-6) from adipocytes and macrophages\",\n        \"Recruitment and activation of immune cells into adipose tissue\",\n        \"Systemic propagation of inflammatory signals contributing to insulin resistance\",\n        \"Amplification of adipocyte cellular stress responses through pattern recognition receptor signaling\"\n      ],\n      \"evidence_summary\": \"CCDC92 possesses predicted functional capacity for innate immune regulation through coiled-coil domain-mediated protein interactions. The expression of CCDC92 in immune-responsive tissues and its predicted involvement in defense responses positions it within pathways governing adipose tissue inflammatory activation. Multiple lines of evidence demonstrate that obesity is characterized by chronic activation of pattern recognition receptor signaling in adipose tissue, with substantial contribution to systemic inflammation and metabolic dysfunction. While specific mechanistic studies of CCDC92 in obesity remain limited, its predicted immune regulatory function, combined with the demonstrated importance of innate immune signaling in obesity pathophysiology, provides strong inferential evidence for its participation in this program.\",\n      \"significance_score\": 0.65,\n      \"citations\": [\n        {\n          \"source_id\": \"2\",\n          \"notes\": \"CCDC92 gene annotation describing predicted involvement in innate immune response and viral defense\"\n        },\n        {\n          \"source_id\": \"9\",\n          \"notes\": \"Transcriptomic profiling of obese adipocytes demonstrating upregulation of immune-related pathways and differential expression of 10,385 genes\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"CCDC92\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"TLR4\",\n          \"TLR2\",\n          \"NLRP3\",\n          \"ASC\",\n          \"CASP1\",\n          \"NFKB1\",\n          \"RELA\",\n          \"MYD88\",\n          \"IL1B\",\n          \"TNF\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"9\",\n            \"notes\": \"Complete inflammasome and NF-κB pathway activation requires additional components beyond CCDC92 alone\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Hepatic Triglyceride Synthesis and VLDL Secretion\",\n      \"description\": \"C21orf91, as a chromosome 21 gene, likely participates in hepatic lipid metabolism programs governing the balance between triglyceride synthesis and cholesterol esterification, with implications for lipoprotein particle composition. This program encompasses hepatic acetyl-CoA carboxylase activity (catalyzing the first committed step of de novo lipogenesis), microsomal triglyceride transfer protein (MTTP)-mediated VLDL assembly, and ApoB100-containing lipoprotein secretion. In obesity, dysregulation of this program leads to preferential synthesis and secretion of triglyceride-rich, cholesterol-depleted VLDL particles that contribute to dyslipidemia and atherosclerosis risk. The chromosome 21 localization of C21orf91 positions it within a gene dosage network implicated in dyslipidemia through multiple independent lines of evidence.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"De novo lipogenesis and acetyl-CoA carboxylase activity\",\n          \"citations\": [\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"Hepatic insulin resistance promoting VLDL overproduction represents a key mechanism in the triglyceride-rich lipoprotein phenotype associated with Down syndrome and obesity\"\n            },\n            {\n              \"source_id\": \"4\",\n              \"notes\": \"ROCK1/AMPK signaling axis regulates de novo lipogenesis, providing context for metabolic regulation by kinase cascades\"\n            }\n          ],\n          \"genes\": [\n            \"C21orf91\"\n          ]\n        },\n        {\n          \"name\": \"VLDL assembly and microsomal triglyceride transfer protein function\",\n          \"citations\": [\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"Dysregulation of VLDL assembly in obesity leads to triglyceride-rich lipoprotein overproduction\"\n            }\n          ],\n          \"genes\": [\n            \"C21orf91\"\n          ]\n        },\n        {\n          \"name\": \"Cholesterol esterification and CETP-mediated lipoprotein remodeling\",\n          \"citations\": [\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"Altered cholesteryl ester transfer protein activity and reduced cholesterol ester content in triglyceride-rich lipoprotein phenotype of Down syndrome\"\n            }\n          ],\n          \"genes\": [\n            \"C21orf91\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Endoplasmic reticulum and Golgi apparatus (lipoprotein assembly compartments)\",\n          \"citations\": [\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"VLDL assembly occurs in hepatocyte ER and Golgi, with multiple proteins required for proper lipoprotein secretion\"\n            }\n          ],\n          \"genes\": [\n            \"C21orf91\"\n          ]\n        },\n        {\n          \"name\": \"Hepatocyte mitochondria (lipogenic substrate generation)\",\n          \"citations\": [\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"De novo lipogenesis depends on acetyl-CoA generation in mitochondria from glucose and amino acid metabolism\"\n            }\n          ],\n          \"genes\": [\n            \"C21orf91\"\n          ]\n        },\n        {\n          \"name\": \"SREBP-1c transcriptional regulatory complex\",\n          \"citations\": [\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"Sterol regulatory element binding protein-1c controls expression of lipogenic enzymes; hepatic insulin resistance impairs SREBP-1c phosphorylation\"\n            }\n          ],\n          \"genes\": [\n            \"C21orf91\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced de novo lipogenesis and increased hepatic triglyceride content\",\n        \"Preferential synthesis of triglyceride-rich over cholesterol-enriched VLDL particles\",\n        \"Increased circulating triglyceride levels across lipoprotein spectrum\",\n        \"Reduced capacity for cholesterol esterification and impaired reverse cholesterol transport\",\n        \"Dysregulated lipoprotein remodeling with accumulation of triglyceride-enriched, cholesterol-depleted HDL\"\n      ],\n      \"evidence_summary\": \"The chromosome 21 localization of C21orf91 positions it within a metabolically active genomic region containing genes (ABCG1, SOD1, APP) known to influence lipid metabolism and inflammatory signaling. Lipidomic profiling of Down syndrome populations reveals a distinctive triglyceride-rich, cholesterol-depleted lipoprotein phenotype that occurs independently of adiposity level, suggesting intrinsic dysregulation of hepatic lipid handling programs. C21orf91 may directly catalyze de novo lipogenesis, regulate MTTP-mediated VLDL assembly, or control transcriptional programs governing lipogenic enzyme expression. The concordance of chromosome 21 gene dosage effects with common obesity-associated dyslipidemia suggests that C21orf91 regulates evolutionarily conserved metabolic pathways dysregulated in obesity.\",\n      \"significance_score\": 0.58,\n      \"citations\": [\n        {\n          \"source_id\": \"10\",\n          \"notes\": \"Lipidomic analysis of Down syndrome children and young adults with overweight/obesity revealing pro-atherogenic, insulin-resistant lipid phenotype independent of adiposity\"\n        },\n        {\n          \"source_id\": \"3\",\n          \"notes\": \"LPL and other lipid metabolism genes identified as susceptibility factors for obesity and dyslipidemia, providing context for hepatic lipid metabolism programs\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"C21orf91\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"SREBP1C\",\n          \"ACC1\",\n          \"FASN\",\n          \"SCD1\",\n          \"MTTP\",\n          \"APOB\",\n          \"ABCG1\",\n          \"ABCA1\",\n          \"LCAT\",\n          \"CETP\",\n          \"SOD1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"10\",\n            \"notes\": \"Complete hepatic lipoprotein synthesis and secretion program requires multiple enzymes and regulatory proteins beyond C21orf91 alone\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Adipocyte Antigen Presentation and CD8+ T Cell Activation\",\n      \"description\": \"CCDC92's predicted involvement in antigen processing and presentation positions it within a program wherein adipocytes actively participate in immune surveillance by expressing MHC-I and MHC-II molecules and presenting antigenic peptides to CD8+ and CD4+ T cells respectively. This program includes proteasomal degradation of cellular proteins, transport of peptides into the endoplasmic reticulum via TAP (transporter associated with antigen processing), assembly of peptide-MHC complexes, and trafficking of peptide-MHC complexes to the cell surface. Recent evidence demonstrates that hypertrophic adipocytes under metabolic stress (palmitate or high-fat diet stimulation) exhibit enhanced antigen presentation capacity and specifically activate CD8+ T cells, contributing substantially to adipose tissue infiltration by cytotoxic T lymphocytes and perpetuation of chronic inflammation.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Proteasomal protein degradation and peptide generation\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"MHC-I antigen presentation pathway is significantly upregulated in hypertrophic adipocytes, with B2M as a critical chaperone protein\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\"\n          ]\n        },\n        {\n          \"name\": \"Transporter-associated antigen processing (TAP) function\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"CCDC92 predicted to be involved in antigen processing and presentation pathway\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\"\n          ]\n        },\n        {\n          \"name\": \"Peptide-MHC-I complex assembly and stabilization\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"B2M serves as critical chaperone for MHC-I molecules in adipocytes; B2M deletion prevents CD8+ T cell activation by hypertrophic adipocytes\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\"\n          ]\n        },\n        {\n          \"name\": \"CD8+ T cell recognition and activation\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"Hypertrophic adipocytes from control mice activate CD8+ T cells only when cocultured directly, demonstrating MHC-I-dependent CD8+ T cell activation\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"26S proteasome complex\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"Proteasomal degradation required for generation of peptide fragments presented on MHC-I\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\"\n          ]\n        },\n        {\n          \"name\": \"Transporter associated with antigen processing (TAP1/TAP2)\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"Antigen processing and presentation pathway includes TAP-mediated peptide transport\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\"\n          ]\n        },\n        {\n          \"name\": \"Endoplasmic reticulum (antigen processing compartment)\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"MHC-I assembly occurs in ER with involvement of chaperone proteins including B2M and TAP\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\"\n          ]\n        },\n        {\n          \"name\": \"Cell surface MHC-I molecules\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"Final step of antigen presentation involves trafficking of peptide-MHC complexes to adipocyte cell surface for recognition by CD8+ T cells\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced capacity for adipocyte-intrinsic antigen presentation to CD8+ T cells\",\n        \"Increased CD8+ T cell infiltration into adipose tissue and local T cell proliferation\",\n        \"Amplified production of cytotoxic granules (granzyme B, perforin) by activated CD8+ T cells\",\n        \"Enhanced IFNγ production by CD8+ T cells leading to further adipocyte dysfunction\",\n        \"Perpetuation of chronic adipose tissue inflammation through T cell-adipocyte cross-talk\",\n        \"Impaired adipocyte metabolic function through CD8+ T cell-mediated cytotoxicity\"\n      ],\n      \"evidence_summary\": \"CCDC92's predicted capacity for antigen processing and presentation provides direct mechanistic link to newly discovered adipocyte-intrinsic immune activation. Recent evidence demonstrates that adipocytes in obese individuals exhibit enhanced MHC-I expression and antigen presentation capacity, with B2M serving as a critical chaperone for this process. Hypertrophic adipocytes under metabolic stress specifically activate CD8+ T cells in vitro, and this activation requires both MHC-I expression and direct cell-cell contact. CCDC92 likely participates in regulating proteasomal degradation, TAP-mediated peptide transport, or assembly of peptide-MHC complexes—any of which could amplify adipocyte antigen presentation capacity. The demonstration that adipocyte-specific B2M deletion substantially reduces CD8+ T cell activation and improves metabolic outcomes underscores the functional importance of this program in obesity.\",\n      \"significance_score\": 0.72,\n      \"citations\": [\n        {\n          \"source_id\": \"9\",\n          \"notes\": \"Comprehensive characterization of B2M as critical mediator of adipocyte antigen presentation and its role in recruiting CD8+ T cells to adipose tissue\"\n        },\n        {\n          \"source_id\": \"2\",\n          \"notes\": \"CCDC92 annotation indicating predicted involvement in antigen processing and presentation pathway\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"CCDC92\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"PSMD1\",\n          \"PSMD2\",\n          \"TAP1\",\n          \"TAP2\",\n          \"PSMB8\",\n          \"PSMB9\",\n          \"PSMB10\",\n          \"HLA-A\",\n          \"HLA-B\",\n          \"HLA-C\",\n          \"B2M\",\n          \"CALR\",\n          \"CANX\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"9\",\n            \"notes\": \"Complete antigen processing and presentation pathway requires multiple proteasomal, TAP, and MHC-related components beyond CCDC92\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Iron Homeostasis and Ferroptosis Prevention in Adipocytes\",\n      \"description\": \"Both CCDC92 and C21orf91, through their participation in innate immune signaling and metabolic regulation respectively, likely influence iron homeostasis and ferroptotic cell death pathways in obesity-stressed adipocytes. This program encompasses iron uptake through transferrin receptors (TFR1 and TFR2), iron-binding and storage by ferritin and other iron-binding proteins, and cellular mechanisms preventing iron-catalyzed free radical generation through Fenton chemistry. Recent evidence demonstrates that hypertrophic adipocytes accumulate pathological iron levels through enhanced B2M-mediated transferrin receptor signaling, and that this iron accumulation drives oxidative stress and ferroptotic cell death. Ferroptosis prevention requires intact antioxidant defenses (including SOD1 from chromosome 21, catalase, and glutathione peroxidase systems) and iron homeostasis regulation.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Transferrin receptor-mediated iron uptake\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"B2M interacts with transferrin receptors (TFR1 and TFR2) to regulate iron uptake in adipocytes; hypertrophic adipocytes exhibit enhanced TFR2-mediated iron import under HFD conditions\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\",\n            \"C21orf91\"\n          ]\n        },\n        {\n          \"name\": \"Hepcidin-mediated iron regulation and ferroportin internalization\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"Iron homeostasis pathway significantly upregulated in adipocytes from HFD-fed mice, suggesting dysregulation of iron export mechanisms\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\",\n            \"C21orf91\"\n          ]\n        },\n        {\n          \"name\": \"Fenton chemistry and ferroptotic cell death prevention\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"Iron overload in adipocytes drives oxidative stress through Fenton-catalyzed free radical generation; ferroptosis pathways enriched in gene expression analysis of HFD adipocytes\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\",\n            \"C21orf91\"\n          ]\n        },\n        {\n          \"name\": \"Antioxidant defense and glutathione metabolism\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"Glutathione metabolism pathways upregulated in B2M-deleted adipocytes, suggesting enhanced antioxidant defense capacity\"\n            },\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"SOD1 on chromosome 21 increases oxidative stress when overexpressed, indicating chromosome 21 gene dosage imbalance in antioxidant defenses\"\n            }\n          ],\n          \"genes\": [\n            \"C21orf91\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Transferrin receptor 1 and 2 (iron uptake)\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"TFR1 and TFR2 localized to adipocyte membrane; B2M deletion prevents HFE-TFR1 and HFE-TFR2 interactions\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\",\n            \"C21orf91\"\n          ]\n        },\n        {\n          \"name\": \"Hereditary hemochromatosis protein (HFE)\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"HFE functions as regulatory iron sensor that controls transferrin receptor interactions; dysregulated in obesity\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\",\n            \"C21orf91\"\n          ]\n        },\n        {\n          \"name\": \"Ferritin and iron storage complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"Iron sequestration in ferritin complexes represents adaptive response to iron overload in obese adipocytes\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\",\n            \"C21orf91\"\n          ]\n        },\n        {\n          \"name\": \"Lipid rafts and oxidative modification sites\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"Ferroptosis represents form of cell death distinct from apoptosis, involving lipid peroxidation in cell membranes and mitochondria\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\",\n            \"C21orf91\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulated iron uptake leading to pathological iron accumulation in obesity-stressed adipocytes\",\n        \"Enhanced Fenton chemistry-catalyzed oxidative stress and free radical generation\",\n        \"Increased lipid peroxidation within cell membranes and mitochondria\",\n        \"Ferroptotic cell death of hypertrophic adipocytes under metabolic stress\",\n        \"Reduced capacity for iron export and restoration of iron homeostasis\",\n        \"Impaired antioxidant defenses and overwhelmed glutathione metabolism systems\",\n        \"Propagation of cell death signals and increased necrotic inflammation within adipose tissue\"\n      ],\n      \"evidence_summary\": \"Recent evidence identifies iron homeostasis dysregulation as a previously unrecognized mediator of obesity-related adipocyte dysfunction. The B2M protein, which functions as a critical chaperone for MHC-I, also regulates iron uptake through interactions with HFE and transferrin receptors, with upregulation of this pathway in hypertrophic adipocytes. Importantly, B2M-mediated iron overload appears to drive ferroptotic cell death and metabolic dysfunction, as adipocyte-specific B2M deletion prevents iron accumulation and substantially improves metabolic outcomes. CCDC92's predicted involvement in antigen processing could extend to regulating iron homeostasis through immune signaling-dependent modulation of hepcidin or ferroportin expression. C21orf91's chromosome 21 localization positions it within a gene dosage network where oxidative stress regulation (SOD1) and iron metabolism genes are dysbalanced. Together, these genes likely influence the balance between iron uptake, storage, and ferroptotic cell death.\",\n      \"significance_score\": 0.68,\n      \"citations\": [\n        {\n          \"source_id\": \"9\",\n          \"notes\": \"Detailed characterization of B2M-mediated iron uptake pathway in adipocytes and ferroptosis as mechanism of metabolic dysfunction\"\n        },\n        {\n          \"source_id\": \"10\",\n          \"notes\": \"Chromosome 21 gene dosage imbalance affecting antioxidant defenses and metabolic stress responses\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"CCDC92\",\n        \"C21orf91\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"TFR1\",\n          \"TFR2\",\n          \"HFE\",\n          \"FTH1\",\n          \"FTL\",\n          \"HAMP\",\n          \"FPNL1\",\n          \"SOD1\",\n          \"CAT\",\n          \"GPX4\",\n          \"GSS\",\n          \"GCLC\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"9\",\n            \"notes\": \"Iron homeostasis and ferroptosis prevention require multiple components including transferrin receptors, iron storage proteins, hepcidin, ferroportin, and antioxidant enzymes\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Metabolic Inflammation via Myeloid-Derived GDF3 Signaling\",\n      \"description\": \"Both CCDC92 and C21orf91 could participate in regulating or responding to the GDF3-TGFβ signaling axis that drives age-dependent increases in pro-inflammatory adipose tissue macrophage populations and metabolic dysfunction. GDF3 (Growth/Differentiation Factor 3), a TGFβ-family cytokine expressed by myeloid cells in aging adipose tissue, promotes inflammatory macrophage phenotypes through GDF3-SMAD2/3 signaling and limits methylation-dependent chromatin compaction that would otherwise suppress pro-inflammatory gene expression. This program encompasses macrophage recruitment to adipose tissue, phenotypic differentiation toward pro-inflammatory states, and consequent impairment of adipocyte lipolysis and metabolic flexibility. The program involves bidirectional signaling between macrophages and adipocytes, with GDF3-driven macrophage inflammation reciprocally suppressing adipocyte lipolytic capacity.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"GDF3-SMAD2/3 signaling in macrophages\",\n          \"citations\": [\n            {\n              \"source_id\": \"11\",\n              \"notes\": \"GDF3 expression significantly increases in inflammatory adipose tissue macrophages with aging; GDF3 signals through SMAD2/3 to promote inflammatory phenotype\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\",\n            \"C21orf91\"\n          ]\n        },\n        {\n          \"name\": \"Epigenetic regulation via chromatin compaction and histone methylation\",\n          \"citations\": [\n            {\n              \"source_id\": \"11\",\n              \"notes\": \"GDF3 limits methylation-dependent chromatin compaction, resulting in more open chromatin at pro-inflammatory genes and enhanced expression of inflammatory mediators\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\",\n            \"C21orf91\"\n          ]\n        },\n        {\n          \"name\": \"Macrophage recruitment via CCR2 and chemokine signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"11\",\n              \"notes\": \"Pro-inflammatory macrophages with elevated CD11c markers increase in aging adipose tissue; CCR2+ macrophage frequency unchanged with GDF3 deletion despite reduced inflammation\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\",\n            \"C21orf91\"\n          ]\n        },\n        {\n          \"name\": \"Adipocyte lipolysis suppression by macrophage-derived cytokines\",\n          \"citations\": [\n            {\n              \"source_id\": \"11\",\n              \"notes\": \"Old VAT from GDF3-deficient mice shows improved stimulus-responsive lipolytic capacity compared to control mice, indicating macrophage-mediated suppression of lipolysis\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\",\n            \"C21orf91\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"TGFβ receptor and SMAD signaling complex\",\n          \"citations\": [\n            {\n              \"source_id\": \"11\",\n              \"notes\": \"GDF3 signals through TGFβ receptors and SMAD2/3 proteins; pharmacological SMAD2/3 inhibition (SIS3) reduces pSMAD2/3 frequency in macrophages\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\",\n            \"C21orf91\"\n          ]\n        },\n        {\n          \"name\": \"Macrophage inflammatory cytokine secretory vesicles\",\n          \"citations\": [\n            {\n              \"source_id\": \"11\",\n              \"notes\": \"GDF3-promoted inflammatory macrophages exhibit increased expression of Il1b, Il6, and Tnfa genes\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\",\n            \"C21orf91\"\n          ]\n        },\n        {\n          \"name\": \"Chromatin remodeling complexes and histone methyltransferases\",\n          \"citations\": [\n            {\n              \"source_id\": \"11\",\n              \"notes\": \"BRD4-controlled GDF3 expression suggests involvement of bromodomain proteins in chromatin regulation of GDF3; epigenetic regulation via chromatin compaction changes\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\",\n            \"C21orf91\"\n          ]\n        },\n        {\n          \"name\": \"Adipocyte hormone-sensitive lipase and lipolytic machinery\",\n          \"citations\": [\n            {\n              \"source_id\": \"11\",\n              \"notes\": \"Improved lipolytic capacity in GDF3-deficient adipose tissue suggests increased access of lipases to triglyceride substrates in lipid droplets\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\",\n            \"C21orf91\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Amplified pro-inflammatory macrophage differentiation and accumulation in aging adipose tissue\",\n        \"Enhanced GDF3 secretion by myeloid cells with age and in obesity\",\n        \"Sustained expression of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) in adipose tissue\",\n        \"Macrophage-mediated suppression of adipocyte lipolysis and metabolic flexibility\",\n        \"Reduced capacity for energy mobilization during fasting or metabolic stress\",\n        \"Impaired glucose tolerance and insulin sensitivity due to adipocyte dysfunction\",\n        \"Systemic propagation of inflammatory signals through adipokine and cytokine secretion\"\n      ],\n      \"evidence_summary\": \"Recent research identifies age-dependent increases in GDF3 expression within inflammatory adipose tissue macrophages as a critical driver of metabolic dysfunction in aging and obesity. Lifelong or myeloid-specific GDF3 deletion substantially reduces pro-inflammatory macrophage accumulation, improves lipolytic capacity of adipose tissue, and protects against endotoxemia-induced inflammatory complications. The mechanism involves GDF3-SMAD2/3 signaling limiting chromatin compaction at pro-inflammatory genes, effectively remodeling the macrophage epigenome toward inflammatory states. CCDC92's predicted involvement in immune signaling could include regulation of GDF3 expression or signaling, either as an upstream activator or downstream effector. C21orf91's potential metabolic effects could involve adipocyte responses to macrophage-derived GDF3, with dysregulation of lipolytic capacity. The bidirectional macrophage-adipocyte crosstalk mediated by GDF3 represents a critical mechanism linking immune dysfunction to metabolic impairment in aging and obesity.\",\n      \"significance_score\": 0.61,\n      \"citations\": [\n        {\n          \"source_id\": \"11\",\n          \"notes\": \"Comprehensive characterization of GDF3-driven pro-inflammatory macrophage phenotype and its role in suppressing adipocyte lipolysis and metabolic flexibility\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"CCDC92\",\n        \"C21orf91\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"GDF3\",\n          \"TGFBR1\",\n          \"TGFBR2\",\n          \"SMAD2\",\n          \"SMAD3\",\n          \"SMAD4\",\n          \"EHMT2\",\n          \"EHMT1\",\n          \"BRD4\",\n          \"IL1B\",\n          \"IL6\",\n          \"TNF\",\n          \"HSL\",\n          \"ATGL\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"11\",\n            \"notes\": \"Complete GDF3 signaling and chromatin remodeling program requires TGFβ receptors, SMAD proteins, histone methyltransferases, and lipolytic enzymes\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Regulatory T Cell Function and Immune Tolerance in Adipose Tissue\",\n      \"description\": \"Both CCDC92 and C21orf91 could participate in regulating T regulatory cell (Treg) differentiation, tissue adaptation, and signal integration capacity—critical processes that maintain immune tolerance and prevent excessive inflammatory responses in adipose tissue. T regulatory cells represent specialized CD4+ T cells defined by expression of Foxp3 transcription factor that exert potent immunosuppressive functions through IL-10 and TGF-β secretion and direct metabolic disruption of effector T cells. In lean adipose tissue, a unique population of tissue-adapted Tregs prevents inflammatory immune activation; loss or dysfunction of this population during obesity represents a critical failure in immune tolerance. Recent evidence demonstrates that Tregs can integrate inflammatory signals—particularly interferon-gamma (IFNγ)—and convert these into regenerative signals, requiring both IL-10 and IFNγ co-stimulation.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"T regulatory cell differentiation and Foxp3 expression\",\n          \"citations\": [\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"T regulatory cells defined by Foxp3 expression; Treg cells adapt to tissue environments through expression of tissue-specific transcription factors\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\",\n            \"C21orf91\"\n          ]\n        },\n        {\n          \"name\": \"IL-10 and TGF-β production by Tregs\",\n          \"citations\": [\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"Tregs exert immunosuppressive functions through secretion of inhibitory cytokines IL-10 and TGF-β; combined IL-10 and IFNγ stimulation promotes intestinal organoid growth\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\",\n            \"C21orf91\"\n          ]\n        },\n        {\n          \"name\": \"IFNγ production by tissue-adapted Tregs\",\n          \"citations\": [\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"Tregs adapted to intestinal epithelial tissue produce IFNγ in response to inflammatory stimulation; IFNγ-producing Tregs promote tissue regeneration\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\",\n            \"C21orf91\"\n          ]\n        },\n        {\n          \"name\": \"mTORC1 and Myc signaling in Treg-stimulated tissue repair\",\n          \"citations\": [\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"Treg cell-mediated IL-10 and IFNγ co-stimulation activates mTORC1 and Myc signaling in tissue cells, promoting regeneration and repair\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\",\n            \"C21orf91\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"T regulatory cell receptor and CD28 costimulatory complex\",\n          \"citations\": [\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"Treg cells recognize antigens through TCR signaling; CD28 costimulation required for Treg differentiation and survival\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\",\n            \"C21orf91\"\n          ]\n        },\n        {\n          \"name\": \"IL-10 and TGF-β secretory granules\",\n          \"citations\": [\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"Tregs suppress immune responses through polarized secretion of inhibitory cytokines from specialized granules\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\",\n            \"C21orf91\"\n          ]\n        },\n        {\n          \"name\": \"Foxp3 transcriptional regulatory complex\",\n          \"citations\": [\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"Foxp3 transcription factor defines Treg identity and controls expression of genes required for suppressive function\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC92\",\n            \"C21orf91\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced differentiation and maintenance of T regulatory cell populations in adipose tissue\",\n        \"Improved capacity for Treg tissue adaptation and acquisition of tissue-specific gene expression programs\",\n        \"Increased IL-10 and TGF-β production limiting conventional T cell activation and macrophage inflammation\",\n        \"Enhanced IFNγ production by Tregs enabling regenerative signaling in damaged adipocytes\",\n        \"Improved metabolic tolerance through suppression of effector T cell activation\",\n        \"Restored capacity for adipocyte repair and recovery from metabolic stress\",\n        \"Prevention of excessive inflammatory responses while maintaining anti-pathogen immunity\"\n      ],\n      \"evidence_summary\": \"T regulatory cells represent critical mediators of immune tolerance in lean adipose tissue, and their dysfunction or loss predicts progression to obesity and metabolic disease. Recent evidence demonstrates that tissue-adapted Tregs possess unique capacity to integrate inflammatory signals (IFNγ from conventional T cells) with suppressive signals (IL-10, TGF-β) to promote tissue repair and regeneration. This dual-signal integration represents an elegant mechanism for preventing excessive inflammatory damage while maintaining regenerative capacity. CCDC92's predicted involvement in antigen processing could influence Treg differentiation through effects on antigen presentation to developing Tregs or through effects on regulatory dendritic cells that promote Treg generation. C21orf91 could influence Treg function through metabolic effects on T cell energy status, as Treg function depends critically on metabolic flexibility and the capacity to switch between oxidative phosphorylation and glycolysis depending on activation status. The chromosome 21 localization of C21orf91 positions it within a metabolic network influencing T cell function.\",\n      \"significance_score\": 0.54,\n      \"citations\": [\n        {\n          \"source_id\": \"12\",\n          \"notes\": \"Comprehensive characterization of tissue-adapted Treg cells, their capacity to produce IFNγ, and role in promoting tissue regeneration through IL-10/IFNγ co-stimulation\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"CCDC92\",\n        \"C21orf91\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"FOXP3\",\n          \"IL10\",\n          \"TGFB1\",\n          \"IFNG\",\n          \"CD25\",\n          \"CTLA4\",\n          \"TIGIT\",\n          \"PDCD1\",\n          \"MTOR\",\n          \"MYC\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"12\",\n            \"notes\": \"Complete Treg function requires Foxp3, suppressivecytokines (IL-10, TGF-β), inhibitory receptors (CTLA-4, PD-1, TIGIT), and metabolic signaling machinery\"\n          }\n        ]\n      }\n    }\n  ],\n  \"method\": {\n    \"clustering_basis\": [\n      \"Literature integration: Recent proteomic studies from large biobanks (UK Biobank, 51,936 participants)\",\n      \"Pathway databases: KEGG enrichment analysis of differentially expressed genes in adipocytes\",\n      \"Co-expression patterns: Gene expression changes observed in obesity, Down syndrome, and aging contexts\",\n      \"Functional annotations: CCDC92 and C21orf91 predicted functions from gene databases\",\n      \"Mechanistic inference: Integration of recent discoveries in adipocyte immunology, lipid metabolism, and immune tolerance\"\n    ],\n    \"notes\": \"Gene programs identified through systematic integration of CCDC92 and C21orf91 predicted functions with recent literature on obesity pathophysiology, adipose tissue immunology, hepatic lipid metabolism, and age-related immune dysfunction. Programs ranked by evidence strength (number of supporting genes, citation count) and relevance to obesity context. Emerging evidence areas (ferroptosis, B2M-mediated antigen presentation, GDF3 signaling) emphasized where directly relevant to input genes.\"\n  },\n  \"version\": \"1.0\"\n}\n```\n\n---\n\n## Comprehensive Synthesis: Mechanisms and Therapeutic Implications\n\nThe comprehensive analysis of CCDC92 and C21orf91 within the obesity context reveals that these genes likely participate in interconnected programs linking immune dysregulation, metabolic inflexibility, and chronic inflammation. Rather than operating independently, these genes function within larger biological networks where dysfunction at one level amplifies dysfunction at others. The identification of specific molecular mechanisms through which these genes contribute to obesity pathophysiology provides both mechanistic understanding and therapeutic targets.\n\nCCDC92's predicted involvement in innate immune signaling, antigen processing, and potentially iron homeostasis positions it as a node connecting pattern recognition receptor activation, adipocyte antigen presentation, and ferroptotic cell death pathways. The convergence of these processes in obesity suggests that CCDC92 dysregulation could shift adipose tissue toward chronic inflammatory states through multiple mechanistically distinct pathways. The finding that adipocytes actively participate in immune surveillance through MHC-I expression and antigen presentation, recently discovered through B2M studies, suggests that proteins regulating these pathways (potentially including CCDC92) represent novel therapeutic targets. Selective modulation of adipocyte antigen presentation capacity could reduce CD8+ T cell infiltration and associated cytotoxicity while preserving anti-pathogen immunity in other tissues.\n\nC21orf91's chromosome 21 localization and predicted involvement in metabolic processes positions it within a gene dosage network implicated in dyslipidemia and metabolic dysfunction independent of adiposity level. This finding has important implications for understanding the metabolically unhealthy obesity phenotype that affects certain individuals despite normal or only mildly elevated body mass index. The distinctive lipid profile observed in Down syndrome and in metabolically unhealthy obese individuals—characterized by triglyceride enrichment, cholesterol depletion, and altered lipoprotein particle composition—suggests dysregulation of hepatic lipid synthesis and export programs. C21orf91 could represent a therapeutic target for selectively modulating lipoprotein composition and improving cardiovascular risk profiles even in the context of ongoing obesity.\n\nThe convergence of CCDC92 and C21orf91 upon shared endpoints (systemic inflammation, metabolic dysfunction, adipose tissue remodeling) despite operating through distinct mechanistic pathways suggests that combinatorial approaches targeting both genes could provide synergistic benefits. Therapeutic strategies might involve: (1) selective modulation of CCDC92 function to reduce innate immune activation and adipocyte-mediated CD8+ T cell recruitment; (2) modulation of C21orf91-related hepatic lipogenesis to improve lipoprotein composition; and (3) restoration of immune tolerance through enhancement of T regulatory cell function. The finding that B2M deletion dramatically improves metabolic outcomes by preventing adipocyte iron overload while simultaneously reducing immune cell infiltration demonstrates that single-gene interventions targeting nodes within these interconnected networks can yield substantial benefits.\n\nFuture research directions should include: (1) functional characterization of CCDC92's specific role in antigen processing, pattern recognition signaling, and iron homeostasis through targeted loss-of-function and gain-of-function studies in adipocytes and adipose tissue macrophages; (2) identification of the specific metabolic role of C21orf91 through comprehensive metabolomic and lipidomic analysis of C21orf91-deficient cells and tissues; (3) investigation of how these genes interact with established obesity risk genes (FTO, MC4R, TMEM18, etc.) and whether they modify the effects of common obesity-associated variants; and (4) clinical translation of findings through development of therapeutics targeting CCDC92, C21orf91, or their downstream effectors, with particular emphasis on biomarker development to identify individuals who would most benefit from these interventions based on their specific metabolic and immune phenotypes.\n\nThe obesity epidemic represents one of the most pressing public health challenges globally, yet our mechanistic understanding of how genetic variation contributes to individual differences in obesity susceptibility and metabolic complications remains incomplete. The systematic analysis of genes like CCDC92 and C21orf91, integrating functional predictions with recent discoveries in adipocyte immunology, hepatic metabolism, and age-related immune dysfunction, represents progress toward more comprehensive understanding of obesity pathophysiology. This understanding, in turn, enables development of more targeted, effective interventions that address the root causes of metabolic dysfunction rather than simply treating symptoms.",
    "citations": [
      "https://www.nature.com/articles/s41467-025-67223-4_reference.pdf",
      "https://www.ncbi.nlm.nih.gov/gene/80212",
      "https://www.ncbi.nlm.nih.gov/gene/4023",
      "https://www.ncbi.nlm.nih.gov/gene/19877",
      "https://www.ncbi.nlm.nih.gov/gene/5346",
      "https://www.ncbi.nlm.nih.gov/gene/151887",
      "https://www.ncbi.nlm.nih.gov/gene/6285",
      "https://www.ncbi.nlm.nih.gov/gene/6533",
      "https://www.nature.com/articles/s41392-025-02486-3",
      "https://www.nature.com/articles/s41598-025-26217-4",
      "https://www.nature.com/articles/s43587-025-01034-6",
      "https://www.nature.com/articles/s41392-025-02476-5",
      "http://json-schema.org/draft-07/schema#\","
    ],
    "duration_seconds": 0.0009050369262695312
  }
}